Statement: The majority of patients in the primary trial suffered from Kidney stones.
Primary_evidence: Adverse Events 1:   Total: 3/19 (15.79%)   Febrile neutropenia 1/19 (5.26%)   Colitis 1/19 (5.26%)   Pain in extremity 0/19 (0.00%)   Nephrolithiasis 0/19 (0.00%)   Pulmonary embolism 1/19 (5.26%)   Dyspnoea 0/19 (0.00%)   Haematoma 0/19 (0.00%) Adverse Events 2:   Total: 4/30 (13.33%)   Febrile neutropenia 1/30 (3.33%)   Colitis 0/30 (0.00%)   Pain in extremity 1/30 (3.33%)   Nephrolithiasis 1/30 (3.33%)   Pulmonary embolism 0/30 (0.00%)   Dyspnoea 1/30 (3.33%)   Haematoma 1/30 (3.33%)